Feasibility and toxicity of weekly paclitaxel-carboplatin in 131 patients with pretreated and non-pretreated solid tumors

Onkologie

Volumn 25, Issue 2, 2002, Pages 152-157

  D'Addario, G ^a   Morant, R ^a   Bohme C ^a   Cerny, T ^a  

^a Kantonsspital ^*  (Switzerland)

Author keywords

Carboplatin; Combination chemotherapy; Multimodal treatment; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGUS CARCINOMA; FEASIBILITY STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; OUTPATIENT; RESPONSE TIME; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PALLIATIVE CARE; SURVIVAL RATE;

EID: 0036249506     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055225     Document Type: Article

References (29)

1. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis
2. DeVore RF 3rd: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
3. Paclitaxel and carboplatin in bladder cancer: Recent developments
4. Paclitaxel and carboplatin in head and neck cancer
5. Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study
6. Dose-finding study of paclitaxel and carboplatin in patients with advenced non-small-cell lung cancer
7. 2) plus carboplatin (6 AUC) in advanced non small cell lung cancer (NSCLC): A multicenter randomized trail
8. Carboplatin and paclitaxel in patients with advanced ovarian cancer: A dose-finding study
9. 2 over 3 h) employed in the treatment of gynecologic malignancies
10. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: Efficacy and adverse effects with special consideration of peripheral neurotoxicity
11. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy
12. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
13. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy
14. Phase II study to evaluate the efficacy of weekly paclitaxel (P) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/-taxane (T) therapy
15. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial
16. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
17. Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a phase II trial
18. Single-agent paclitaxel in the treatment of breast cancer: Phase I and II development
19. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)
20. One-hour paclitaxel infusions: Review of safety and efficacy
21. The pharmacokinetics of a 1-h paclitaxel infusion
22. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
23. Carboplatin as a potentiator of radiation therapy
24. Investigation of taxol as a potential radiation sensitizer
25. In vitro studies of Taxol as a radiation sensitizer in human tumor cells
26. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
27. Chemoradiotherapy in non-small cell lung cancer: Paclitaxel/carboplatin/radiotherapy in regionally advanced disease
28. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center study 94-001
29. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer